KR840008147A - 디하이드로피리딘 항 극소 빈혈 및 항고혈압제 - Google Patents
디하이드로피리딘 항 극소 빈혈 및 항고혈압제 Download PDFInfo
- Publication number
- KR840008147A KR840008147A KR1019840001209A KR840001209A KR840008147A KR 840008147 A KR840008147 A KR 840008147A KR 1019840001209 A KR1019840001209 A KR 1019840001209A KR 840001209 A KR840001209 A KR 840001209A KR 840008147 A KR840008147 A KR 840008147A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- aryl
- nhch
- heterocyclic
- Prior art date
Links
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title claims 2
- 208000007502 anemia Diseases 0.000 title 1
- 230000003276 anti-hypertensive effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 7
- 150000001412 amines Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- -1 imidazolyl carbonyl Chemical class 0.000 claims 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002540 isothiocyanates Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- (a) 내지 (f)의 방법을 특징으로 하여 일반식(I)의 1,4-디하이드로 피리딘 및 이들의 약제학적으로 허용되는 산부가염을 제조하는 방법 및 경우에 따라 생성물의 약제학적으로 허용되는 염을 형성하는 (a)내지 (f)의 각 방법. (a) 일반식(II)의 아민을 시안화칼륨 또는 일반식(III)의 이소시아네이트 또는 이소티오시아네이트와 반응시켜서 일반식(I)의 화합물들을 제조하고(여기에서 R4는 -C(=X)R5이고, X는 또는 S이며, R5는 NH2, NH(C1-C4알킬), NH(C3-C|6시클로알킬), NHCH2CO2(C1-C4알킬), NH-아릴, HNCO-아릴 또는 NH-헤테로시클릭 또는 NHCO-헤테로 시클릭 그룹이다), R5가 NHCH2Cl2(C1-C4알킬)일 때, 그 화합물을 진한 암모니아와 반응시켜 R5가 NhCH2CONH2인 화합물을 수득하거나 또는 묽은 염기로 가수분해시켜서 R5가 NHCH2CO2H인 화합물을 제조하거나; (b) 일반식(II)의 아민을 티오포스겐과 반응시키고 생성된 이소티오시아네이트를 암모니아 또는 (C1-C4)알킬아민, (C3-C|6)-시클로알킬아민 또는 (C1-4)디알킬아민과 각기 반응시켜서 일반식(I)의 화합물들을 (R4는 -C(=S)R5이고 R5는 NH2, NH(C1-C4알킬), NH(C3-C6시클로알킬) 또는 N(C1-C4알킬)2인)제조하거나; (c) 일반식(II)의 아민과 N,N′-카보닐디이미다졸을 반응시키고 생성된 이미다졸릴 카보닐 유도체를 일반식 NH2CH2CONH2, NH2CH2CH2NH2, NH2-헤테로 시클릭, NH2NH2또는 NH2NHCO2CH2CH3의 화합물과 각기 반응시켜 일반식(I)의 화합물등(R4는 -C(=X)R5이고, R5는 NHCH2CONH2, NHCH2CH2NH|2NH-헤테로시클릭, NH NH2또는 NHNHCO2CH2CH3인)을 제조하거나; (d) 일반식(II)의 아민을 일반식 R9CO2H의 산, 또는 이들의 무수물, 산 클로라이드 또는 활성화된 유도체(여기에서 R9는 각기 H, CF3, C1-C4알킬 또는 헤테로시클릭 그룹인)와 반응시켜서 일반식(I)의 화합물(R4는 C(=X)R5이고 X는 0이며 R5는 H, CF3, C1-C4알킬 또는 헤테로 시클릭 그룹인)을 제조하거나; (e) 일반식(II)의 아민을 일반식(Ⅳ)의 화합물(R6및 R10이 하기와 같은)과 반응시키거나, R10이 SCH3일 때는 생성물을 (C1-C4)알킬아민, 일반식 NH2(CH2)mN(C1-C4알킬)2의 (m은 2내지 4)디 알킬아미노-알킬아민, 또는 헤테로시클릭 아민과 반응시켜서 일반식(I)의 화합물들을(R4는 -C(=NR6)R7이고 R6은 하기와 같고, R7은 NH2, NHCO(C1-C4알킬), NH(C1-C4알킬), NH(CH2)m(C1-C4알킬)2(m은 2 내지 4), 또는 NH-헤테로시클릭 그룹인)제조하고, R6이 H일 때는 C1-C4알킬 또는 할로겐화 아릴 설포닐과 반응시켜 R6이 SO2(C1-C4알킬) 또는 SO2아릴인 일반식(I)의 화합물들을 제조하거나; (f) 일반식(II)의 아민을 설파이드 또는 일반식(Ⅴ)의 설포닐 클로라이드와 반응시켜서 R4가 SO2-R5이고 R5는 하기와 같은 일반식(I)의 화합물들을 제조한다.상기식에서 R은 아릴 또는 헤테로아릴이고; R1및 R2는 각기 독립적으로 C1-C4알킬 또는 2-메톡시에틸이며; n은 2,3 또는 4이고; H, C1-C4알킬, CH2CO2(C1-C4알킬) 또는 CH2CN이며 R4은 다음 일반식의 그룹이다.(여기에서 Z는 0또는 S이고; R5는 C1-C4알킬, NH2, NH(C1-C4알킬), NH(C3-C6시클로알킬), N(C1-C4알킬)2, NHCH2CO2(C1-C|4알킬), NHCH2CONH2, NHCH2CO2H, NH(CH2)|2NH2, NH2NH2, NHNHCO2(C1-C4알킬), NH-아릴, NHCO-아릴 또는 헤테로시클릭, NH-헤테로시클릭 또는 NHCO-헤테로시클릭 그룹이며 또는 R4가 C(=0)R5일 때 R5는 H 또는 CF3일 수 있다; R6은 H, CN, CO2(C1-C4알킬), CO(C1-C4알킬), SO2(C1-C4알킬), SO2-아릴, SO2NH2, SO2N(C1-C4알킬)Small2, NO2또는 아릴이고; R7은 NH2, NH(C1-C4알킬), NHCO(C1-C4알킬), NH(CH2)mN(C1-C4알킬)2이다. (m은 2내지 4 또는 NH-헤테로시클릭 그룹이다): R8은 각기 C1-C4저급알킬, C3-C6시클로알킬, CH2CO2(C1-C4알킬), 아릴, CO-아릴 또는 헤테로시클릭 또는 CO-헤테로시클릭 그룹이고, R9는 H,CF3, C1-C4알킬, 또는 헤테로 시클릭 그룹이며, R10은 SCH3, NH2또는 NHCO (C1-C4)알킬이고, R11은 C1-C4저급알킬 NH(C1-C4)알킬, NH(C3-C6시클로알킬) N(C1-C4알킬)2, NH-아릴, NHCO-아릴, 또는 헤테로시클릭, NH헤테로시클릭 또는 NHCO-헤테로시클릭 그룹이다.
- 제1항에 있어서 R이 “아릴”이고 “아릴”은 니트로, 할로, C1-C4알킬, C1-C4알콕시, 하이드록시, 트리플루오로메틸 및 시아노에서 선택한 하나 또는 두 치환체로 치환한 페닐, 1- 및 2-나프틸이며; 또는 R이 “헤테로아릴”이고, “헤테로아릴”은 벤조푸라닐; 벤조티에닐; 메틸, 티오메틸, 할로 또는 시아노로 경우에 따라 치환된 피리딜; 퀴놀일; 벤조사졸릴; 벤즈티아졸릴; 푸릴; 피리미디닐; 티아졸릴; 2,1,3-벤조사디아졸-4-일; 2,1,3-벤조티아디아졸-4-일; 및 할로 또는 C1-C4알킬로 경우에 따라 일치환된 티에닐인 방법.
- 제2항에 있어서, R이 2-클로로페닐 또는 2,3-디클로로페닐인 방법.
- 제3항에 있어서, R1이 CH3이고 R2가 C2H5인 방법.
- 제1항 내지 4항중 어느 하나에 있어서, n이 2인 방법.
- 제1항 내지 5항중 어느 하나에 있어서, R3이 H 또는 CH3인 방법.
- 제1항 내지 6항 중의 어느 하나에 있어서, R5가 H, NHCH3, NHCH2CONH2또는 2-피리돈-5-일 때 R4가 COR5이고; R5이 NH2일 때 R4가 CSR5이며; R6이 CN이고 R7이 NHCH3일 때 R4가 C(=NR6)R7이고; R이 NH2, NHCH3, NH시클로펜틸, 2-티에닐, 8-퀴놀일 또는 2-(4-메틸페라진-1-일)피리-5-딜일 때 R4가 SO2R5인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838306666A GB8306666D0 (en) | 1983-03-10 | 1983-03-10 | Therapeutic agents |
| GB8306666 | 1983-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR840008147A true KR840008147A (ko) | 1984-12-13 |
Family
ID=10539350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840001209A KR840008147A (ko) | 1983-03-10 | 1984-03-09 | 디하이드로피리딘 항 극소 빈혈 및 항고혈압제 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4590195A (ko) |
| EP (1) | EP0119050B1 (ko) |
| JP (1) | JPS59175466A (ko) |
| KR (1) | KR840008147A (ko) |
| AU (1) | AU546634B2 (ko) |
| DE (1) | DE3477379D1 (ko) |
| DK (1) | DK168378B1 (ko) |
| ES (3) | ES8506275A1 (ko) |
| FI (1) | FI840955A (ko) |
| GB (1) | GB8306666D0 (ko) |
| GR (1) | GR81872B (ko) |
| HU (1) | HU191220B (ko) |
| IE (1) | IE57116B1 (ko) |
| IL (1) | IL71187A0 (ko) |
| PH (1) | PH20692A (ko) |
| PL (2) | PL246574A1 (ko) |
| PT (1) | PT78219B (ko) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8421039D0 (en) * | 1984-08-17 | 1984-09-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB8501395D0 (en) * | 1985-01-19 | 1985-02-20 | Pfizer Ltd | Dihydropyridine anti-ischaemic & anti-hypertensive agents |
| EP0233228A1 (en) * | 1985-08-06 | 1987-08-26 | Boehringer Mannheim Italia S.P.A. | Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines |
| IT1204421B (it) * | 1986-06-27 | 1989-03-01 | Boehringer Biochemia Srl | 2-(aminoalchiltio)metil-1,4-diidropiridine,un metodo per la loro preparazione e composizioni farmaceutiche che le contengono |
| IT1201454B (it) * | 1985-08-19 | 1989-02-02 | Boehringer Biochemia Srl | 1,4-diidropiridine-2-sostituite |
| GB8527698D0 (en) * | 1985-11-09 | 1985-12-11 | Pfizer Ltd | Dihydropyridine antiischaemic & antihypertensive agents |
| EP0225175A3 (en) * | 1985-11-28 | 1988-12-28 | FISONS plc | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof |
| DE3621104A1 (de) * | 1986-06-24 | 1988-01-07 | Heumann Pharma Gmbh & Co | 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| IT1197012B (it) * | 1986-07-29 | 1988-11-25 | Boehringer Biochemia Srl | 2-(aciltio) metil diidropiridine, un processo per la loro preparazione e composizioni farmaceutiche che le contengono |
| FR2602231B1 (fr) * | 1986-08-04 | 1988-10-28 | Adir | Nouveaux derives de la dihydro-1,4 pyridine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| IT1213555B (it) * | 1986-12-11 | 1989-12-20 | Boehringer Biochemia Srl | 2 metiltiometildiidropiridine, un processo per laloro preparazione e composizioni farmaceutiche che le contengono. |
| IT1215381B (it) * | 1987-03-12 | 1990-02-08 | Boehringer Biochemia Srl | Farmaceutiche che le contengono. carbonil- e solfonil- derivati di 2-(aminoalchiltio)metil-1,4-diidropiridine, un metodo per la loro preparazione e composizioni |
| GB8710493D0 (en) * | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Dihydropyridines |
| NZ229828A (en) * | 1988-08-09 | 1992-03-26 | Squibb & Sons Inc | Aryl cyanoguanidine derivatives and pharmaceutical compositions |
| US5278169A (en) * | 1988-08-09 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Method of treating or prevention of fibrillation of the heart |
| IE71183B1 (en) * | 1988-12-27 | 1997-01-29 | Takeda Chemical Industries Ltd | Guanidine derivatives their production and insecticides |
| AT5874U1 (de) | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| EP1499592A4 (en) * | 2002-04-13 | 2010-01-13 | Hanlim Pharmaceutical Co Ltd | AMLODIPINE NICOTINATE AND PROCESS FOR PREPARING THE SAME |
| US20070066619A1 (en) * | 2002-10-07 | 2007-03-22 | Artesian Therapeutics, Inc. | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity |
| MXPA05003640A (es) * | 2002-10-07 | 2005-11-17 | Artesian Therapeutics Inc | Compuestos de dihidropiridina que tienen capacidad simultanea para bloquear los canales de calcio del tipo l y para inhibir la actividad de la fosfodiesterasa del tipo 3. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3974278A (en) * | 1973-07-12 | 1976-08-10 | Bayer Aktiengesellschaft | 1,4-Dihydropyridine esters |
| US4177278A (en) * | 1977-04-05 | 1979-12-04 | Bayer Aktiengesellschaft | 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use |
| JPS5547656A (en) * | 1978-09-29 | 1980-04-04 | Dainippon Pharmaceut Co Ltd | 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative |
| SE7910521L (sv) * | 1979-12-20 | 1981-06-21 | Haessle Ab | Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma |
| DE3022030A1 (de) * | 1980-06-12 | 1981-12-17 | Bayer Ag, 5090 Leverkusen | 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel |
| CS228917B2 (en) * | 1981-03-14 | 1984-05-14 | Pfizer | Method of preparing substituted derivatives of 1,4-dihydropyridine |
| DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| US4568677A (en) * | 1983-07-23 | 1986-02-04 | Pfizer Inc. | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents |
-
1983
- 1983-03-10 GB GB838306666A patent/GB8306666D0/en active Pending
-
1984
- 1984-02-29 DK DK135884A patent/DK168378B1/da not_active IP Right Cessation
- 1984-03-05 US US06/586,514 patent/US4590195A/en not_active Expired - Lifetime
- 1984-03-06 EP EP84301452A patent/EP0119050B1/en not_active Expired
- 1984-03-06 DE DE8484301452T patent/DE3477379D1/de not_active Expired
- 1984-03-06 PH PH30346A patent/PH20692A/en unknown
- 1984-03-08 FI FI840955A patent/FI840955A/fi not_active Application Discontinuation
- 1984-03-08 IL IL71187A patent/IL71187A0/xx unknown
- 1984-03-08 PT PT78219A patent/PT78219B/pt not_active IP Right Cessation
- 1984-03-08 PL PL24657484A patent/PL246574A1/xx unknown
- 1984-03-08 ES ES530379A patent/ES8506275A1/es not_active Expired
- 1984-03-08 PL PL25277384A patent/PL252773A1/xx unknown
- 1984-03-08 GR GR74031A patent/GR81872B/el unknown
- 1984-03-09 KR KR1019840001209A patent/KR840008147A/ko not_active Application Discontinuation
- 1984-03-09 IE IE585/84A patent/IE57116B1/en not_active IP Right Cessation
- 1984-03-09 HU HU84964A patent/HU191220B/hu unknown
- 1984-03-09 AU AU25464/84A patent/AU546634B2/en not_active Ceased
- 1984-03-10 JP JP59046375A patent/JPS59175466A/ja active Pending
- 1984-10-31 ES ES537269A patent/ES537269A0/es active Granted
- 1984-10-31 ES ES537268A patent/ES8507111A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK168378B1 (da) | 1994-03-21 |
| PH20692A (en) | 1987-03-24 |
| IE57116B1 (en) | 1992-05-06 |
| GB8306666D0 (en) | 1983-04-13 |
| PL252773A1 (en) | 1985-11-19 |
| AU546634B2 (en) | 1985-09-12 |
| ES537268A0 (es) | 1985-08-16 |
| PT78219A (en) | 1984-04-01 |
| HU191220B (en) | 1987-01-28 |
| PT78219B (en) | 1986-08-12 |
| EP0119050A2 (en) | 1984-09-19 |
| US4590195A (en) | 1986-05-20 |
| ES8507112A1 (es) | 1985-08-16 |
| AU2546484A (en) | 1984-09-13 |
| DK135884A (da) | 1984-09-11 |
| ES530379A0 (es) | 1985-07-01 |
| EP0119050B1 (en) | 1989-03-22 |
| ES8506275A1 (es) | 1985-07-01 |
| DE3477379D1 (en) | 1989-04-27 |
| DK135884D0 (da) | 1984-02-29 |
| EP0119050A3 (en) | 1987-07-01 |
| PL246574A1 (en) | 1985-08-13 |
| ES8507111A1 (es) | 1985-08-16 |
| FI840955A0 (fi) | 1984-03-08 |
| ES537269A0 (es) | 1985-08-16 |
| FI840955A (fi) | 1984-09-11 |
| GR81872B (ko) | 1984-12-12 |
| IE840585L (en) | 1984-09-10 |
| IL71187A0 (en) | 1984-06-29 |
| JPS59175466A (ja) | 1984-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR840008147A (ko) | 디하이드로피리딘 항 극소 빈혈 및 항고혈압제 | |
| ATE94534T1 (de) | Antiarrhythmische verbindungen. | |
| KR830009025A (ko) | 1,4-디하이드로피리딘 유도체의 제조방법 | |
| DE3782883D1 (de) | Pyridincarboxamid-derivate und ihre verwendung als fungizides mittel. | |
| KR920009798A (ko) | 제초제로서의 카복스아미드 유도체, 그들의 제법, 및 그들을 함유하는 제초 조성물 | |
| KR870011129A (ko) | 디스타마이신 a 동족체 및 이의 제조방법 | |
| KR900014365A (ko) | 신규의 벤즈이미다졸 및 아자벤즈이미다졸 유도체, 이들의 제조방법, 합성 중간체 및 이들을 함유하며 특히 심장 혈관계 질환과 십이지장 궤양의 치료에 유효한 약리적 조성물 | |
| DE68906183D1 (de) | 2'-desoxy-5-fluoruridinderivate. | |
| KR850005829A (ko) | 2-시아노벤즈이미다졸 유도체의 제조방법 | |
| KR850003716A (ko) | 치환 및 미치환된 2-카바모일니코틴산과 3-퀴놀린카르복실산의 제조방법 | |
| KR840005118A (ko) | 헤테로사이클릭 아민의 제조방법 | |
| KR960704877A (ko) | 이미다졸리딘온 유도체, 이의 산부가염 및 노인성 치매 치료제 (Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia) | |
| KR880011118A (ko) | 2-페닐 이미다졸 유도체를 이용한 살충방법 | |
| GB1342024A (en) | Triazine herbicides | |
| KR910004545A (ko) | 신규 아조페닐 화합물,이를 함유한 조성물, 이에 제조방법 및 살균제로서 이들의 이용 | |
| KR850001173A (ko) | 2-치환된 4-페닐이미다졸 아미딘 유도체의 제조방법 | |
| KR890008144A (ko) | 1,2,3,4-테트라하이드로-5-니트로-피리미딘 유도체 | |
| DE68922145D1 (de) | Herbizide Acrylonitrilderivate. | |
| KR900003166A (ko) | 신규 푸릴티아졸 유도체, 그것의 제조방법 및 그 화합물을 함유하는 약학적 조성물 | |
| KR880001580A (ko) | N-(2-시아노-2-옥스이미노아세틸)-아미노니트릴 | |
| KR830002744A (ko) | 구아니딘 화합물의 제조방법 | |
| GB1047245A (ko) | ||
| GB1141249A (en) | New quinazoline compounds and methods for their production | |
| GB817745A (en) | 2-thiohydantoins | |
| KR910000675A (ko) | 치환된 3-아미노시드논 이민, 이의 제조방법 및 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |